curriculum vitae 1. personal data - unispital basel...2002 - current commission for the board...

CURRICULUM VITAE

1. Personal Data Name: Christoph Andreas MEIER

Date and Place of Birth: March 16, 1962; Basel, Switzerland Nationality: Swiss (BS & ZH)

Professional Address: Chief Medical Officer

University Hospital Basel Spitalstrasse 22 CH-4051 Basel Switzerland Tel +41 61 328 7374 2. Current Positions since March 2016 Chief Medical Officer, University Hospital Basel, Switzerland since 2005 Professor ("professeur associé"; since 2014 under the new law of the University for external collaborators 'professeur titulaire'), Medical Faculty, University of Geneva, Switzerland since 2008 Editor-in-Chief, Best Practice & Research in Clinical Endocrinology (IF 4.9), Elsevier Publishers, Oxford U.K. since 2009 Board of Directors, Novartis Venture Fund, Basel & Boston, USA since 2015 Appraisal Committee, Swiss Medical Board, Bern 3. Diplomas and Academic Titles 3.1. Education 1973 - 1981 Classical School ("Humanistisches Gymnasium"); Basel, Switzerland (type B) 3.2. Diplomas, Licenses 1987 Swiss Federal Medical Diploma, University of Basel Medical School, Switzerland 1988 ECFMG Certificate No 0-416-903-3, USA 1995 - 1998 Limited License 95-2026-98, Massachusetts Board of Registration, USA 1997 Board Certification (FMH) in Internal Medicine and Endocrinology & Diabetology, Switzerland 1998 Expert in radioprotection for open sources for the medical applications of radioactive substances, Swiss Federal Office of Public Health 1998-2006 Medical License, Canton of Geneva, Switzerland 2006 - 02.2016 Medical License, Canton of Zurich, Switzerland 3.3. Academic Titles 1988 M.D. Thesis (‘Viability testing of radioactively labeled human granulocytes'), Prof. Helmut Mäcke, Division of Nuclear Medicine, University of Basel, Switzerland 1998 - 2001 SCORE A ('Maître d'enseignement et de recherche suppléant'), Div. of Endocrinology and Diabetes, Dept. of Medicine, University Hospital Geneva 1999 - 2004 Privat-Docent ('Regulation of gene expression by PPARs'), Medical Faculty, University of Geneva (UniGE), Switzerland 2004 - 2005 Chargé de cours, Medical Faculty, UniGE

Christoph A. Meier 2

2005 - current Associate Professor of Medicine (2005-2014 'professeur associé', >2014 'professeur titulaire' under the new law of the university), Medical Faculty, University of Geneva 4. Pregraduate Training 1981 Research Assistant Dept. of Physics, ETH, Zurich and Arosa 1982-1987 Medical School, University of Basel, Switzerland 5. Professional Activities 1988 - 1990 Postgraduate Course in Experimental Medicine and Biology; University of Zurich Medical School (Prof. J. Zapf) and Dept. of Biochemistry, University of Basel, Switzerland (Prof. P. Walter) 1990 - 1991 Postdoctoral Fellow, National Institutes of Health, NIDDK, Molecular, Cellular and Nutritional Endocrinology Branch; Bethesda, MD, USA 1991 - 1992 Visiting Associate, National Institutes of Health, NIDDK, Molecular and Cellular Endocrinology Branch; Bethesda, MD, USA 1992 - 1995 Medical Resident, Medical Clinic II (Prof. F. Waldvogel), University Hospital Geneva (HUG), Switzerland Principal Investigator, Laboratory of Molecular Endocrinology, HUG 1995 - 1998 Clinical Fellowship in Endocrinology and Metabolism, Massachusetts General Hospital, Harvard Medical School, Boston, USA 1996 - 1998 Howard Hughes Medical Institute Physician Fellow, Endocrine Division, Massachusetts General Hospital, and Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston (75%). Chief Resident, Medical Clinic II (Prof. F. Waldvogel), HUG (25%) 1998 - 2006 Attending Physician, Medical Clinics I and II (Profs. A-F. Junod and F Waldvogel) 1998 - 2001 Attending Physician, Div. of Endocrinology, Diabetes & Nutrition, HUG 2001 - 2006 Head, Endocrine Unit, Div. of Endocrinology, Diabetes & Nutrition, HUG 2006 - 02.2016 Chief, Department of Internal Medicine & Specialties, Triemli Hospital, Zürich, Switzerland and Member of the Board of Directors of the Triemli Hospital 6. Teaching 6.1. University of Geneva 1998 - 2006 Yearly Course 'Internal Medicine' (24 hours/y) 1998 - 2006 Yearly Course 'Thyroid disorders' (10 hours/y) 1998 - 2006 Yearly Course 'Diabetes' (6 hours/y) 1998 - 2006 Internal Medicine Seminars for medical students (12 hours/y) 2000 - 2006 Yearly Course 'Introduction to Internal Medicine' (16 hours/y) 2003 - 2006 Yearly Course 'Introduction to Gynecology' (6 hours/y) 2003 - 2007 Programme Director for the optional study modules (2nd, 3rd, 4th and 5th years) 2007 - current Programme Director for the optional study modules (4th and 5th years) 2007 - current Participation in the module 'Obesity: metabolic, clinical and social aspects' (coordinator: Prof. F. Rohner-Jeanrenaud) 2007 - current Teaching of medical students during their Elective in Internal Medicine at the Triemli Hospital 6.2. University of Zurich 2006 - current Clinical course in Internal Medicine (VVZ-Nr. 0663) Endocrine Tumorboard (VVZ-Nr. 1026) Electives in Internal Medicine 6.3. Postgraduate and Continuing Medical Education 1994 - 2005 Lecturer, Postgraduate Course in Experimental Medicine and Biology, University of Zurich Medical School


2006 - current Organisation of the weekly Medical Grand Rounds, EBM-Seminars, Journal Club and Clinical Pathological Conferences at the Triemli Hospital, Zurich 2013 - current Lecturer, CAS in Health Care Management, college-M, Berne 6.4. Paramedical 2001 - 2006 Endocrinology for dieticians 2001 - 2006 Endocrine Emergencies for nurses 6.5. Supervisor of examinations 1998 - 2006 Final Examinations for Medical students 2000 - 2005 Examinations for Board Certification (FMH) in Endocrinology and Diabetology 2005 - current Examination for Board Certification (FMH) in Internal Medicine 6.6. Committees 2003 - 2006 Member of the Programme Committee for the 4th-6th year of medical studies (UniGE) 2003 - 2006 President, Committee for the optional activities for medical students (2nd - 5th year; UniGE) 2004 President of the working group for the coordination of teaching in endocrinolgy and diabetes (UniGE) 2003 - 2006 Member of the Committee for the reform of the Federal Examination in Internal Medicine (UniGE) 2005 - 2006 Member of the committee for the reform of the medical curriculum according to the Bologna model (UniGE) 7. Research Activities - Metabolic control of inflammation (Member of the Competence Center for Systems Physiology and Metabolic Diseases, CC-SPMD of the Federal Institute of Technology Zurich) - Cost-effective utilization of diagnostic tools & Shared-decision Making 8. Administrative Boards 1999 - 2001 Full Member of the Council of the University of Geneva ('Conseil de l'Université') 1999 - 2002 Steering Committee, Fonds Wilsdorf, Dept. of Internal Medicine, Geneva 2002 - 2006 Member of the Dean's Working Group on the future of diabetes, endocrinology and metabolism (GeMet) 2002 - current Scientific Council of the Swiss Orphanet (UniGE 2003 - 2006 Member of three Committees for Clinical Research: Dean's committee, committee of the Dept. of Internal Medicine, and research committee of the Dept. of Primary Care Medicine; all UniGE 2003 - 2006 Member of the M.D.-Ph.D. Programme Committee, Medical faculty, UniGE 2004 – 2006 Member of the Task force ‘Metabolism’ within the programme ‘Science, Vie & Société’ of the rectorate (Universities of Geneva, Lausanne and the EPFL) 2004 – 2006 Member of the Council of the Clinical Section, Medical Faculty, UniGE 2008 - current Member of the Swiss Fluoride-Iodine Committee (Swiss Academy of Medical Sciences) 9. Distinctions 1988 Development Award form the Swiss Academy for Medical Science 1988 Scholarship Award from the University of Zurich for the Postgraduate Course in Experimental Medicine and Biology 1990 Fellowship Award from the Swiss National Science Foundation 1993 Guest Lecturer at the National Institutes of Health, NIDDK, Bethesda, USA 1994 Prix Bizot, Award for Medical Research, University of Geneva 1995 European Merck von Basedow Research Price, German Endocrine Society 1996 Award of the Swiss Society of Internal Medicine 1996 Howard Hughes Postdoctoral Research Fellowship Award for Physicians


1997 Investigator Award (SCORE A) of the Swiss National Science Foundation 2002 Albert Reynold Lecture, Swiss Society for Endocrinology and Diabetes 2004 Prix Pfizer in Clinical Immunology since 2007 Member of the Ludwig Heilmeyer Gesellschaft für Fortschritte in der inneren Medizin 10. Membership in Professional Societies 1988 - current Foederatio Medicorum Helveticorum (FMH) 1989 - current Swiss Endocrine Society (SGED-SSED) 1993 - current Endocrine Society, USA 1993 - 1998 European Thyroid Association (ETA) 1995 - 1998 American Association for Clinical Endocrinology (AACE) 1995 - 1998 Massachusetts Medical Society 1997 - current Swiss Society for Internal Medicine (SGIM) 1999 - 2006 Geneva Medical Association (AMG) 2001 - 2006 Society of staff physicians of the University Hospitals Geneva ('AMAHUG') 2002 - 2006 French Society of Endocrinology (SFE) 2006 - current American College of Physician (ACP) 2006 - current Zurich Medical Association (AGZ) 2006 - current Swiss Association of Staff Physicians (VLSS) 2006 - current Zurich Association of Internists (ZVI) 11. Official Functions 2001 - 2009 Member, Council of the Swiss Endocrine Society ('SSED') 2001 - 2006 Delegate of the SSED at the FMH for Guidelines in Endocrinology and Diabetology 2002 - 2006 Delegate of the SSED at the Commission for Postgraduate Formation of the FMH 2002 - current Commission for the Board Examination FMH in Internal Medicine (SGIM) 2003 - 2005 Vice-president, Swiss Society for Endocrinology and Diabetes ('SSED') 2006 - 2009 President, Swiss Society for Endocrinology and Diabetes 2006 - current Member of the Board of Directors; Triemli Hospital Zurich 2009 - current Board of Directors, Novartis Venture Fund, Basel, Switzerland 2014 - current Scientific Advisory Board, Clinical Research Center,

University & University Hospitals of Geneva 2014 - current Scientific Advisory Board, Private Foundation of the

University Hospitals of Geneva 2015 – current Appraisal Committee, Swiss Medical Board 12. Expert Panels and Editorial Activities 12.1. Expert Panels 1996 Thesis expert, Faculty of Science, University of Lausanne, Switzerland 1996 Consultant Endocrinology for American Telemedicine Consultant for Boehringer Ingelheim International GmbH 1997 Expert Panel, Environmental Endocrine Disrupters, Environmental Protection Agency, USA 1999 Thesis Expert, Faculty of Sciences, University of Lausanne Thesis Expert, Medical Faculty, Marseille, France 1999 Expert for the Biotechnology and Biological Sciences Research Counsil, U.K. 2001 Thesis Expert, Faculty of Sciences, University of Lausanne 2001 - current Reviewer for M.D. Theses; UniGE 2001 - current Expert for the Swiss National Science Foundation (grant review) 2003 - 2005 Member, Programme Organizing Committee for the European Congress of Endocrinology in Goetheborg in 2005 2004 External expert, Medical Research Council, Australia 2005 - current Expert for the Agence Nationale de Recherche, France


2005 - 2006 Member, Programme Organizing Committee for the European Congress of Endocrinology in Glasgow in 2006 2006 - current Member of the Steering board for medications of the City hospitals of Zurich 2007 - 2008 Member of the Scientific Committee for the annual congress of the French Endocrine Society, Lille 2008 2007 Expert for the Medical Faculty of the University of Basel (promotions) 2007 - current Consultant for Debiopharm, Luasanne, Switzerland 2008 Ph.D. Thesis advisory committee, ETH Zurich (B. Meersburger) 2008 Ph.D. Thesis opponent; University of Goetheborg, Sweden 2009 - 2013 Swissmedic – Human Medicines Expert Committee 2009 Ph.D. Thesis advisory committee, ETH Zurich (F. Möst) 2011 Nomination committee for Dr. Micheline Louis-Courvoisier (promotion to associate professor), University of Geneva Medical School 2013 - 2014 Expert for the Swiss Medical Board 12.2. Editorial and Reviewing Activities 1995 - 2001 Highlights Editor, European Journal of Endocrinology 2002- 2007 Editor, Baillière’s Clinical Endocrinology & Metabolism 2004 - current Editorial Board, Revue Médicale Suisse 2008 - current Editor-in-Chief; Best Practice & Research in Clinical Endocrinology & Metabolism (Elsevier, IF 4.9) 2012 - current Editor, Therapeutische Umschau 12.3. Reviewer for the following Journals: Age & Ageing Arteriosclerosis, Thrombosis and Vascular Biology Arthritis Research Biochemistry Clinical Drug Investigation Clinical Endocrinology Dermatology Diabetes European Journal of Endocrinology FASEB Journal Fetal Diagnosis and Therapy Journal of Biological Chemistry Journal of Clinical Endocrinology and Metabolism Jounal of Clinical Investigation Journal of Investigative Dermatology Journal of Molecular Endocrinology Journal of Nuclear Medicine Journal of Pathology Molecular Cellular Endocrinology Nature Clinical Practice Endocrinology & Metabolism Swiss Medical Weekly 13. Research Grants 13.1 Principal Investigator 1992 - 1995 Swiss National Science Foundation (grant # 32-33568.92) Modulation of thyroid hormone action in peripheral tissues 1993 - 1995 Swiss Cancer Society (# FOR407) Expression of c-erbA thyroid hormone receptor subtypes in human cancer 1996 - 1999 Collaborative Research Agreement with Boehringer Ingelheim International: Phosphorylation of peroxisome proliferator-activated receptors 1996 - 1998 Howard Hughes Medical Institute (#808331): Interaction of the peroxisome proliferator-activated receptors with other nuclear proteins


1998 - 2001 Swiss National Science Foundation SCORE A (#3231-51 957.97) and Research Grant (#3200-52 192.97) Signal transduction pathways and hormonal cross-talk in developing and mature adipocytes: Role of peroxisome proliferator-activated receptors 1998 Helmut Horton Foundation Importance of Co-Activator Molecules for Nuclear Hormone Receptors: Adenovirus-mediated gene transfer into insulin-sensitive cells and tissues 1999 Novartis Foundation (#99B31) Regulation of the expression of PPARs in the colon: A nutritional link to colon cancer 2001 - 2004 Swiss National Science Foundation (#3200-064078.01) until November 2001: SCORE A (#3231-51 957.97/2) PPARs and leptin as metabolic and immunological regulators 2001 Academic Society Geneva (# 2001/102) Signaling mechanisms of leptin 2004 - 2005 Fondation Ernest Boninchi, Rectorat University of Geneva Production of chemokines by adipose tissue and the impact on cardiovascular disease 2004 - 2005 Fondation Ernst et Lucie Schmidheiny Impact of adipokines on cadiovascular disease and metabolism 2004 - current Swiss National Science Foundation, 3200B0-103618/1 Adipose tissue as a regulator of inflammation 13.2 Co-Principal Investigator 1993 - 1998 Swiss National Science Foundation (#3200-037536.93) Thyroid hormone action and metabolism 14. Patents 1. U.S. Provisional Patent Application for:

ADIPOSE TISSUE AS A TARGET FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISEASES by Meier C.A. and Dayer J.-M. Application no. 60/403,566, filed on 13 August 2002.

15. Supervision of theses and diplomas 1996 - 1997 Director, Diploma in Biochemistry of Véronique Pauli 1997 - 1998 Director, Diploma in Biochemistry of Eva Hammar 1997 - 2000 Co-director, Ph.D. thesis Nathalie Lameloise 1998 - 2000 Co-director, M.D. thesis of Anne Brawand 1998 - 2002 Director, Ph.D. thesis of Magali G. Dreyer 1999 - 2002 Director, M.D. thesis of Alexandra Calmy 2000 - 2002 Director, Diploma in Biochemistry of Lynne Salomon 2000 - 2006 Co-director, M.D. thesis of P. Kohler 2000 - 2006 Director, Ph.D. thesis of Emmanuel Somm 2015 Director M.D. thesis of Silvia Richner


Bibliography (IF = impact factor) 1. Original papers (peer-reviewed journals)

1. Coleman R.E., Meier C.A., Rubens R.D., Fogelman I.: Comparison of 99mTc-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer. Nuclear Medicine Communications 9 (7): 481-485 (1988) IF 1.2

2. Meier C.A., Fabbro D., Meyhack I., Hemmings B., Olbrecht U., Jakob A., Walter P.: Effect of hypothyroidism and thyroid hormone replacement on the level of protein kinase C and protein kinase A in rat liver. FEBS Letters 282 (2): 397-400 (1991) IF 3.7

3. Raederstorff D., Meier C.A., Moser U., Walter P.: Hypothyroidism and thyroxin substitution affect the n-3 fatty acid composition of rat liver mitochondria. Lipids 26 (10): 781-787 (1991) IF 2.0

4. Meier C.A., Dickstein B.M., Ashizawa K., McClaskey J.H., Muchmore P., Ransom S.C., Menke J.B., Hao E.H., Usala S.J., Bercu B.B., Cheng S.Y., Weintraub B.D.: Variable transcriptional activity and ligand binding of mutant beta 1 3,5,3'-triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Molecular Endocrinology 6 (2): 248-258 (1992) IF 7.6

5. Meier C.A., Maisey M.N., Lowry A., Müller J., Smith M.A.: Interindividual differences in the pituitary-thyroid axis influence the interpretation of thyroid function tests. Clinical Endocrinology 39 (1): 101-107 (1993) IF 2.8

6. Meier C.A., Parkison C., Chen A., Ashizawa K., Meier-Heusler S.C., Muchmore P., Cheng S.-Y., Weintraub B.D.: Interaction of human beta1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor alpha: T3 response element-dependent dominant negative potency. Journal of Clinical Investigation 92 (10): 1986-1993 (1993) IF 14

7. Meier C.A., Braverman L.E., Ebner S.A., Daniels G.H., Ross D.S., Daraska D., Davies T.F., Valentine M., DeGroot L., Curran P., McEllin K., Reynolds J., Robbins J., Weintraub B.D.: Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 78 (1), 188-196 (1994) IF 5.8

8. Meier-Heusler S.C., Zhu X., Juge-Aubry C., Pernin A., Burger A.G., Cheng S.-y., Meier C.A.: Modulation of thyroid hormone action by mutant thyroid hormone receptors, c-erbAalpha2 and peroxisome proliferator-activated receptor: Evidence for different mechanisms of inhibition. Molecular and Cellular Endocrinology 107 (1): 55-66 (1995) IF 2.4

9. Juge-Aubry C., Gorla A., Pernin A., Lemberger T., Wahli W., Burger A.G., Meier C.A.: Peroxisome proliferator activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor: Possible role of a leucine zipper-like heptad repeat. Journal of Biological Chemistry 270 (30): 18117-18122 (1995) IF 7.7

10. Meier-Heusler S., Pernin A.,Liang H., Goumaz M.O., Burger A.G., Meier C.A.:Quantitation of tau1 triiodothyronine receptor mRNA in human tissues by competitive reverse transcription polymerase chain reaction. Journal of Endocrinological Investigation 18 (10): 767-773 (1995) IF 1.0

11. Shalev A., Siegrist-Kaiser C.A., Yen P.M., Wahli W., Burger, A.G., Chin W.W., Meier C.A.: The peroxisome proliferator-activated receptor alpha is a phosphoprotein:Regulation by insulin. Endocrinology 137 (10): 4499-4502 (1996) IF 5.4

12. Lemberger T., Braissant O., Juge-Aubry C., Keller H., Saladin R., Staels B., Auwerx J., Burger A.G., Meier C.A., Wahli W.: PPAR tissue distribution and interactions with other hormone-signaling pathways. Annals of the New York Academy of Sciences 804: 231-251 (1996) IF 1.9

13. Huber-Gieseke T., Pernin A., Huber O., Burger A.G., Meier C.A.: Lack of loss of heterozygosity at the c-erbA beta locus in gastrointestinal tumors. Oncology 54 (3): 214-219 (1997). See erratum 54 (5): 370 (1997). IF 3.0

14. Juge-Aubry C., Pernin A., Favez T., Burger, A.G., Wahli W., Meier C.A., Desvergne B.: DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural


peroxisome proliferator response elements: Importance of the 5’ flanking region. Journal of Biological Chemistry 272 (40): 25252-25259 (1997) IF 7.7

15. Siegrist-Kaiser C.A., Pauli V., Juge-Aubry C.E., Boss O., Pernin A., Cusin I., Rohner-Jeanrenaud F., Chin W.W., Burger A.G., Zapf J., Meier C.A.: Direct effects of leptin on brown and white adipose tissue. Journal of Clinical Investigation 100 (11): 2858-2864 (1997) IF 14

16. Gorla-Bajszczak A., Juge-Aubry C., Pernin A., Burger A.G., Meier C.A.: Conserved amino acids in the ligand-binding and tau i domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR. Molecular and Cellular Endocrinology 147 (1-2): 37-47 (1999) IF 2.4

17. DeVito M., Biegel L., Brouwer A., Brown S., Brucker-Davis F., Cheek A.O., Christensen R., Colborn T., Cooke P., Crissman J., Crofton K., Doerge D., Gray E., Hauser P., Hurley P., Kohn M., Lazar J., McMaster S., McClain M., McConnell E., Meier C., Miller R., Tietge J., Tyl R.: Screening methods for chemicals that alter thyroid hormone action, function and homeostasis. Environmental Health Perspectives 107 (5): 407-415 (1999) IF 2.5

18. Juge-Aubry C.E., Hammar E., Siegrist-Kaiser C.A., Pernin A., Takeshita A., Chin W.W., Burger A.G. and Meier C.A.: Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor α by phosphorylation of a ligand-independent trans-activating domain. Journal of Biological Chemistry 274 (15): 10505-10510 (1999) IF 7.7

19. Gorla-Bajszczak A., Siegrist-Kaiser C.A., Boss O., Burger, A.G., Meier, C.A.: Expression of peroxisome proliferator-activated receptors in lean and obese Zucker rats. European Journal of Endocrinology 142 (1): 71-78 (2000) IF 2.4

20. Calmy A., Lopez-Liuchi J.V., Borst F., Meier C.A.: Comparison of current guidelines on the treatment of hypercholesterolemia in secondary prevention: Can the Swiss recommendations be simplified? Schweizerische Medizinische Wochenschrift 130: 535-544 (2000) IF 0.3

21. Borst F., Thurler G., Breant C., Lehner-Godinho B., Calmy A., Meier C.: Finding similar cases within a hospital information system. Stud Health Technol Inform 77:875-879 (2000)

22. Juge-Aubry C.E., Kuenzli S., Sanchez J.-C., Hochstrasser D., Meier C.A.: Peroxisomal bifunctional enzyme binds and activates the AF-1 region of PPAR alpha. Biochemical Journal 353: 253-258 (2001) IF 4.3

23. Gabay C., Dreyer M.G., Pellegrinelli N., Chicheportiche R., Meier C.A.: Leptin directly induces the secretion of IL-1 receptor antagonist in human monocytes. Journal of Clinical Endocrinology and Metabolism 86: 783-791 (2001) IF 5.4

24. Triponez F., Simon S., Robert J., Andereggen E., Ussel M., Bouchardy C., Oritt J., Meier C.A., Burger A., Spiliopoulos A.: Cancers de la thyroïde: Expérience genevoise. Annales de Chirurgie 126: 969-976 (2001) IF 0.6

25. Meier C.A., Bobbioni E., Gabay C., Assimacopoulos-Jeannet F., Golay A., Dayer J.-M.: Interkleukin-1 receptor antagonist serum levels are increased in human obesity: A possible link to the resistance to leptin? Journal of Clinical Endocrinology and Metabolism 87: 1184-1188 (2002) IF 5.4

26. Meier C.A., Chicheportiche R., Juge-Aubry C.E., Dreyer M.G., Dayer J.-M.: Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine 18 (6): 320-328 (2002) IF 2.0

27. Cettour-Rose P., Cusin I., Pernin A., Meier C.A:, Visser T., Burger A.G., Rohner-Jeanrenaud F.: Central stimulatory effect of leptin on T3 production is mediated by brown adipose tissue type 2 deiodinase Am J Physiol Endocrinol Metab 283 (5): E980-987 (2002) IF 3.3

28. Simon S., Tötsch M., Schmidlin F., Iselin C., Meier C.A.: Adrenal cortical pheochromocytoma: A case report of a rare entity. Exp Clin Endocrinol & Diabetes 111 (2): 111-114 (2003) IF 1.6


29. Calmy A., Hirschel B., Hans D., Karsegard L., Meier C.A.: Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy AIDS 17 (5): 12-14 (2003) IF 8.0

30. Dreyer M.G., Juge-Aubry C.E., Gabay C., Lang U., Rohner-Jeanrenaud F., Dayer J.-M., Meier C.A.: Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor NFκB/PU.1 binding site. Biochemical Journal 370 (2): 591-599 (2003) IF 4.3

31. Meier C.A., Chicheportiche R., Dayer J.M.: IP-10, but not RANTES, is upregulated by leptin in monocytic cells. Cytokine 21 (1): 43-47 (2003) IF 2.0

32. Juge-Aubry C., Somm E., Giusti V., Pernin A., Chicheportiche R., Verdumo C., Rohner-Jeanrenaud F., Burger D., Dayer J.-M., Meier C.A.: Adipose tissue is a major source of interleukin-1 receptor antagonist: Upregulation in obesity and inflammation. Diabetes 52 (5): 1104-1110 (2003) IF 8.3

33. Feilchenfeldt J., Tötsch M., Sheu S.-Y., Robert J., Spiliopoulos A., Frilling A., Schmid .W., Meier C.A.: Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immuno-histochemistry. Modern Pathology 16 (11): 1117-1123 (2003) IF 3.8

34. Russell A., Feilchenfeldt J., Schreiber S., Praz M., Crettenand A., Gobelet C., Meier C.A., Bell D., Kralli A., Giacobino J.-P., Dériaz O.: Endurance training in humans leads to fiber type-specific increases in levels of PPARgamma coactivator-1 and PPARgamma in skeletal muscle. Diabetes 52 (12): 2874-2881 (2003) IF 8.3

35. Feilchenfeldt J., Bründler M.-A., Soravia C., Tötsch M., Meier C.A.: Peroxisome proliferator- activated receptors and associated transcription factors in colon cancer: Reduced expression of PPAR-gamma coactivator 1 (PGC-1) Cancer Letters 203 (1): 25-33 (2004) IF 2.3

36. Juge-Aubry C.E., Somm E., Chicheportiche R., Burger D.,Pernin A., Cuénod-Pittet B, Quinodoz P., Giusti V., Dayer J.-M., Meier C.A.: Regulatory effects of interleukin-1 and interferon-β on human adipose tissue. Journal of Clinical Endocrinology and Metabolism 89 (6): 2652 (2004) IF 5.4

37. Pelte M.F., Schwaller J., Cerrato C., Meier C.A.: Proopiomelanocortin expression in a metastatic breast carcinoma with ectopic ACTH secretion. The Breast Journal 10 (4): 350-354 (2004)

38. Philips J.-C., Petite C., Willi J.-P., Buchegger F., Meier C.A.: Effect of PPARγ agonist rosiglitazone on dedifferentiated thyroid cancers Nuclear Medicine Communications 25 (12): 1183-1186 (2004) IF 1.2

39. Juge-Aubry C.E., Somm E., Pernin A., Alizadeh N., Dayer J.-M., Meier C.A.: Adipose tissue is a regulated source of IL-10 Cytokine 29 (6): 270-274 (2005) IF 2.0

40. Cettour-Rose P., Theander-Carrillo C., Asensio C., Klein M., Visser T.J., Burger A.G., Meier C.A., Rohner-Jeanrenaud F.: Hypothyroidism in rats decreases peripheral glucose utilization, a defect partially corrected by central leptin infusion. Diabetologia 48 (4): 624-633 (2005) IF 5.7

41. Brown S.A., Fleury-Olela F., Nagoshi E., Hauser C., Juge C., Meier C.A., Chicheportiche R., Dayer J.-M., Albrecht U., Schibler U.: The period length of peripheral circadian rhythms differs among human individuals. PLoS Biology 3 (10): e338 (2005) IF 13.9

42. Kyle U.G., Jolliet P., Genton L., Meier C.A., Mensi N., Graf J.-D., Chevrolet J.-C., Pichard C.: Clinical evaluation of metabolic stress state in medical ICU patients: A prospective blind study. Intensive Care Medicine 31: 1669-1675 (2005) IF 3.0

43. Henrichot E., Juge-Aubry C.E., Wohlwend A., Pernin A., Pache J.-C., Velebit V., Dayer J.-M., Meda P., Chizzolini C., Meier C.A.: Production of chemokines by perivascular adipose tissue: A role in the pathogenesis of atherosclerosis? Arteriosclerosis, Thrombosis and Vascular Biology 25 (12): 2594-2599 (2005) IF 7.4


44. Somm E., Henrichot E., Pernin A., Juge-Aubry C.E., Muzzin P., Dayer J.-M., Nicklin M., Meier C.A.: Decreased fat mass in interleukin-1 receptor antagonist deficient mice: Impact on adipogenesis, food intake and energy expenditure. Diabetes 54 (12): 3503-3509 (2005) IF 8.8

45. De Gottardi A., Pazienza V., Pugnale P., Bruttin F., Rubbia-Brandt L., Juge-Aubry C.E., Meier C.A., Hadengue A., Negro F.: Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Alimentary Pharmacology & Therapeutics 23 (1): 107-114 (2005) IF 4.0

46. Somm E., Cettour-Rose P., Asensio C., Charollais A., Klein M., Theander-Carrillo C., Juge-Aubry C.E., Dayer J.-M., Nicklin M., Meda P., Rohner-Jeanrenaud F., Meier C.A.: Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity of rodents Diabetologia 49 (2): 387-393 (2006) IF 5.6

47. Dayer J.-M., Chicheportiche R., Juge-Aubry C., Meier C.: Adipose tissue has anti-inflammatory properties: Focus on IL-1 receptor antagonist Annals of the New York Academy of Sciences 1069: 444-453 (2006) IF 1.9

48. Mouche S., Mkaddem S.B., Wang W., Katic M., Tseng Y.-H., Carnesecchi S., Steger K., Foti M., Meier C.A., Muzzin P., Kahn C.R., Ogier-Denis E., Szanto I.: Reduced expression of the NADPH oxidase NOX4 is a hallmark of adipocyte differentiation Biochim Biophys Acta - Molecular Cell Research 1773 (7): 1015-27 (2007) IF 6.9

49. Ybarra J., Lehmann T., Golay A., Juge-Aubry C.E., Roux-Lombard P., Dayer J.-M., Meier C.A.: Gender-based dimorphic pattern for interleukin-1 receptor antagonist in type 2 diabetes mellitus. Diabetes Metab 34 (1): 75-91 (2008) IF 2.2

50. Clément S., Juge-Aubry C., Conzelman S., Pazienza V., Pittet-Cuenod B., Meier C.A., Negro F.: Monocyte cheomattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology 48 (3): 799-807 (2008) IF 10.4

51. Thalmann S. Juge-Aubry C.E. and Meier C.A.: Explant cultures of white adipose tissue Methods in Molecular Biology 456: 195-199 (2008)

52. Osann Franziska, Mair-Noack Claude, Meier C.A., Ritter Simon: Kalk im Hirn Swiss Medical Forum 9 (34): 597 (2009)

53. Gerber B., Manser C., Wielsi P., Meier C.A.: A family with diabetes and heart failure. BMJ Case Reports doi:10.1136/bcr.01.2010.2613 (2010)

54. Ritter S., Guertler T., Meier C.A., Genoni M.: Cardiogenic shock due to pheochromocytoma rescued by extracorporeal membrane oxygenation. Interactive CardioVascular and Thoracic Surgery 13 (1): 112-113 (2011)

55. Stoppa-Vaucher S., Dirlewanger M., Meier C.A., de Moerloose Ph., Reber G., Roux-Lombard P., Combescure C., Saudan S., Schwitzgebel V.M. : Inflammatory and prothrombotic states in obese children of european descent Obesity 20 (8): 1662-1668(2012) IF 3.5

56. Schmitz C., Berchtold P., Laifer G., Meier C.A.: Optimierung im Spital Schweizerische Aerztezeitung 93 (24): 964-967 (2012)

57. Rey A., Thoenes M., Fimmers R., Meier C.A., Bramlage P.: Diabetes prevalence and metabolic risk profile in an unselected population visiting pharmacies in Switzerland - the AMAVITA survey. Vascular Health and Risk Management 8: 541-547 (2012)

58. Schmitz C., Berchtold P., Laifer G., Meier C.A.: Herausforderung Vernetzung - Wie Prozessoptimierung im Spital gelingen kann. Zeitschrift für Organisationsentwicklung No.1: 76-81 (2013)

59. Wiggli B., Imhof E., Meier C.A., Laifer G.: Water, water, everywhere The Lancet 381: 776 (2013) IF 25

60. Selby K., Cornuz J., Neuner-Jehle S. Perrier A., Zeller A., Meier C.A., Rodondi N., Gaspoz J.-M.: “Smarter Medicine”: 5 Interventionen , die in der ambulanten allgemeinen Inneren Medizin vernieden werden sollten. Schweizerische Aerztezeitung 95 (20): 767-770 (2014)


61. Selby K., Cornuz J., Neuner-Jehle S. Perrier A., Zeller A., Meier C.A., Rodondi N., Gaspoz J.-M.: “Smarter Medicine”: Für mehr Effizienz in der Allgemeinmedizin. PrimaryCare 14 (10): 166-167 (2014)

62. Schmitz C., Berchtold P., Meier C.A., Tschacher W.: It’s not about stress: Psychological capital of medical residents. submitted (2015)

2. Reviews 1. Meier C.A.: Interpretation of thyroid function tests: A novel concept based on interindividual

differences in the pituitary-thyroid axis. Experimental and Clinical Endocrinology 102 (Suppl. 2): 27-32 (1994) IF 1.0

2. Meier C.A.: Physiopathologie des récepteurs hormonaux nucléaires. Médecine & Hygiène 53 (2071): 1068-1072 (1995)

3. Meier C.A.: Modulation der Schilddrüsenhormon-Wirkung im Zellkern. Endokrinologie-Informationen 19 (3): 87-88 (1995)

4. Meier C.A.: Molekulare Endokrinologie von Schilddrüsenkrankheiten. Schweizerische Medizinische Wochenschrift, 125 (49): 2367-2378 (1995) IF 0.3

5. Meier C.A.: Regulation of gene expression by nuclear hormone receptors. Journal of Receptor and Signal Transduction Research 17 (1-3): 319-335 (1997) IF 1.9

6. Meier C.A.: Novel Aspects of Leptin Secretion and Action. Endocrine News 22 (1): 1+16 (1997)

7. Meier C.A., Biller, B.M.K.: Clinical and Biochemical evaluation of Cushing’s syndrome. Endocrinology and Metabolism Clinics of North America 26 (4): 741-762 (1997) IF 2.3

8. Meier C.A.: Nodules thyroïdiens: Approche diagnostique et thérapeutique Revue Médicale de la Suisse Romande 119: 487-491 (1999)

9. Buchegger F., Slosman, D.O., Meier C., Mach J.-P., Bischof Delaloye A.: La radiothérapie systémique isotopique. Médecine & Hygiène 57: 141-1422 (1999)

10. Meier C.A.: Hyperthyreose: Vor- und Nachteile der medikamentösen, chirurgischen und Radiojodbehandlung. Therapeutische Umschau, 56 (7): 364-368 (1999)

11. Pralong F.P., Meier C.A.: Recommandations pour le diagnostic des tumeurs hypophysaires. Bulletin des Médecins Suisses 81: 2594-2595 (2000)

12. Simon S., Meier C.A.: Diagnostic du syndrome de Cushing. Médecine & Hygiène 59 (2334): 358-362 (2001)

13. Meier C.A.: Thyroid nodules: pathogenesis, diagnosis and treatment Baillière's Best Practice & Research in Clinical Endocrinology & Metabolism 14 (4): 559-575 (2000) IF 4.9

14. Juge-Aubry C.E., Meier C.A.: Cutting Edge - Immunomodulatory actions of leptin. Molecular & Cellular Endocrinology 194 (1): 1-7 (2002) IF 2.4

15. Petite C., Meier C.A.: Cholestérol: Qui ne faut-il pas traiter? Médecine & Hygiène 60: 1669-1674 (2002)

16. Meier C.A.: Opinion - Médecine anti-âge Bulletin de l'Ordre des Médecins (Belgique) October: 81-90 (2002)

17. Meier C.A.: Médecine anti-âge: Est-ce vraiment nécessaire? Swiss Medical Forum 2 (51/52): 1218 (2002)

18. Meier C.A.: Acquisitions thérapeutiques 2003 - Endocrinologie Médecine & Hygiène 2464: 3-35 (2004)

19. Meier C.A., Perrenoud J.-J.: Médecine anti-âge & gériatrie: Un appel au pragmatisme Médecine & Hygiène 2466: 185-190 (2004)


20. Meier C.A.: Anti-aging-Medizin Internistische Praxis 44 (2): 405-410 (2004)

21. Petite C, Meier C.A.: Prise en charge de l'hypothyroïdie Médecine & Hygiène 2480: 926-932 (2004)

22. Meier C.A.: Anti-aging-Medizin Arzneimitteltherapie-Kritik 36 (2): 123-128 (2004)

23. Petite C., Girardin F., Meier C.A.: Inhibiteurs de l'HMGCo-A réductase: un choix fondé sur les faits Pharma-Flash 31: no. 1-2 (2004)

24. Petite C., Meier C.A.: Nodules thyroïdiens et goitres: Le traitement chirurgical Swiss Medical Forum 4: 1090-1096 (2004)

25. Meier C.A. Acquisitions thérapeutiques 2004 - Endocrinologie Revue Médicale Suisse 1 (1): 24-26 (2005)

26. Fatio S., Dirlewanger M., Meier C.A., Schwitzgebel V.: Traitement par hormone de croissance: Phase de transition de l’enfance à l’âge adulte Revue Médicale Suisse 1 (6): 426-431 (2005)

27. Meyer P., Meier C.A.: Mise au point sur la déhydroépiandrosterone (DHEA) Revue Médicale Suisse 1 (6): 415-418 (2005)

28. Meier C.A.: Relation entre l’industrie pharmaceutique et les médecins; Problèmes et defies Courrier Médical Valaisan 34: 14-15 (2005)

29. Juge-Aubry C., Henrichot E., Meier C.A.: Adipose tissue: A regulator of inflammation Best Practice & Research in Clinical Endocrinology & Metabolism 19 (4) 547-566 (2005) IF 4.9

30. Meyer P. and Meier C.A.: Acquisitions thérapeutiques 2005 - Endocrinologie Revue Médicale Suisse 2 (47): 15-18 (2006)

31. Meier C.A., Fokstuen S. et al: Recommandations pour le dépistage génétique des syndromes MEN-1 et MEN2 Swiss Medical Forum 6: 299-303 (2006)

32. Juge-Aubry C.E. and Meier C.A.: Sécrétion de cytokines par le tissu adipeux: Effets métaboliques et vasculaires Journ Annu Diabetol Hotel Dieu 129-40 (2006)

33. Thalmann S. and Meier C.A.: Acne and "mild" adrenal hyperplasia. A short critical review. Dermatology 213: 277-278 (2006) IF 1.6

34. Thalmann S. and Meier C.A.: Local adipose tissue depots as cardiovascular risk factors Cardiovascular Research 75: 690-701 (2007) IF 5.8

35. Meier C.A., Thalmann S.: Tissu adipeux, inflammation et athérome Bulletin de l'Académie Nationale de Médecine 191 (no 4-5): 897-910 (2007)

36. Binz K., Haldemann A., Schweizer I., Gürtler T. and Meier C.A.: Differenziertes Schilddrüsenkarzinom: Wissenswertes für die Praxis Swiss Medical Forum 43: 818-822 (2008)

37. Haldemann A, Meier C.A.: Strumaknoten oder Schilddrüsentumor - Wie Sie klinisch relevante Fälle erkennen und abklären Hausarzt Praxis No 5: 7-11 (2008)

38. Thalmann S, Meier C.A.: Explant cultures of white adipose tissue Methods Mol Biol 456: 195-199 (2008)

39. Thalmann S, Meier C.A.: Nodules thyroïdiens: (F)utilité des outils diagnostiques Mise au Point Cliniques d'Endocrinologie, Nutrition et Métabolisme, 37-46 (2008)

40. Meier C.A.: Role of Imaging in Thyroid Disease IDKD 2008

41. Calmy A, Bernasconi E., Meier C.A., Hirschel B. and Toutous-Trellu L: 10 ans de lipodystrophie - Un syndrome encore méconnu Revue Médicale Suisse 184: 2755-2757 (2008)


42. Laifer G., Gaudenz R., Meier C.A.: Behandlungspfade in der Medizin Swiss Medical Forum 9 (26-27): 470-472 (2009)

43. Henzen C., Christ E., Elsässer P., Fischer-Taeschler D., Diem P., Wielsi P., Meier C.A., Schönle E., Lehmann R.: Erhöhtes Krebsrisiko durch Insulin Glargin (Lantus)? Swiss Medical Forum 9 (42): 755-756 (2009)

44. Thalmann S, Meier C.A.: Haben Glitazone noch einen Platz in der Behandlung des Typ-2-Diabetes ? Swiss Medical Forum 10 (6): 114-116 (2009)

45. Meyer M.R., Meier C.A.: Übergewicht und kardiovaskuläres Risiko: Neues zur Pathogenese und Therapie Swiss Medical Forum 10 (21): 358-362 (2010)

46. Meier C.A.: Das metabolische Syndrom: Nutzen (oder nicht?) in der Praxis Revue Médicale Suisse 279: 269-270 (2011)

47. Bischof T.R., Weishaupt D., Meier C.A., Ritter S.: Morgagni-Hernie Swiss Medical Forum 11 (18): 322-323 (2011)

48. Kurzen J.-L., Schwegler I., Berthold C., Suhner M., , Meier C., Laifer G.: Eine Injektion mit Folgen Swiss Medical Forum 11 (19): 340-341 (2011)

49. Wiggli B., Tüller D., Dinges S., Meier C.A.: Rezidivierende Synkopen mit seltener Ursache Swiss Medical Forum 12 (14-15): 316-318 (2012)

50. Meier C.A.: Guest Editor Endokrinologie in der Praxis Therapeutische Umschau 68: Volume 6 (2011)

51. Binz K., Haldemann A., Meier C.A.: Das differenzierte Schildrüsenkarzinom – das Wichtigste für die Praxis Therapeutische Umschau 68 (6): 291-295 (2011)

52. Baumgartner B., Weishaupt D., Meier C.A., Ritter S.: Respiratorische Insuffizienz bei Chilaiditi-Syndrom Swiss Medical Forum 13 (37): 733-734 (2013)

53. Mondin F.P., Eich G., Meier C.A., Ritter S.: Generalisierter Ausschlag und rasch progrediente Dyspnoe bei einer jungen Frau Swiss Medical Forum 13 (50): 1041-1043 (2013)

54. Schneiter R., Weber M., Zulewski H., Meier C.A.: Diagnose und Therapie des differenzierten Schilddrüsenkarzinoms Swiss Medical Forum 14 (9): 171-176 (2014)

55. Meier C.A.: Guest Editor Andropause & Menopause Therapeutische Umschau 71: Volume 4 (2014)

56. Meier C.A.: Guest Editor Schilddrüsenstörungen Der informierte Arzt, 4: Volume 6 (2014)

57. Anand G.W., Meier C.A., Zulewski H.: Rationale Abklärungsstrategie bei Schilddrüsenknoten Der informierte Arzt, 4 (6): 22-29 (2014)

58. Binz K., Haldemann A., Meier C.A.: Das differenzierte Schildrüsenkarzinom – das Wichtigste für die Praxis Journal ASMAC 2014.08.30

3. Editorials & Comments 1. Meier C.A.: Advances in the understanding of the molecular basis of obesity.

European Journal of Endocrinology 133, 761-763 (1995) IF 2.4

2. Meier C.A.: Mechanisms of immunosuppression by glucocorticoids. European Journal of Endocrinology 134, 50 (1996) IF 2.4

3. Meier C.A.: Co-activators and co-repressors: Mediators of gene activation by nuclear hormone receptors. European Journal of Endocrinology 134, 158-159 (1996) IF 2.4


4. Shalev A., Meier C.A.: Peroxisome proliferator-activated receptors: A nuclear hormone receptor involved in adipocyte differentiation and lipid homeostasis. European Journal of Endocrinology 134, 541-542 (1996) IF 2.4

5. Meier C.A.: Leptin secretion and action: an update. European Journal of Endocrinology 134, 543-544 (1996) IF 2.4

6. Meier C.A.: Molecular pathology of familial central diabetes insipidus. European Journal of Endocrinology 134, 683-684 (1996) IF 2.4

7. Meier C.A.: Regulation of cholesterol synthesis: of SCAP, SREBP, CBP and more. European Journal of Endocrinology 136, 271-272 (1997) IF 2.4

8. Meier C.A.: Molecular insights into the regulation of energy intake and expenditure. European Journal of Endocrinology, 137, 20-21 (1997) IF 2.4

9. Meier C.A.: Novel pharmacological approaches to the prevention and treatment of non-insulin-dependent diabetes mellitus. European Journal of Endocrinology 137, 224-225 (1997) IF 2.4

10. Meier C.A.: Role of novel antiresorptive agents for the prevention and treatment of osteoporosis. European Journal of Endocrinology 139, 18-19 (1998) IF 2.4

11. Meier C.A.: Orexins and anorexins: Thoughts for food. European Journal of Endocrinology 139: 148-149 (1998) IF 2.4

12. Lopez-Liuchi J.V., Meier C.A.: Transcriptional repression: Lessons from thyroid hormone action and promyelocytic leukaemia. European Journal of Endocrinology 139: 260-262 (1998) IF 2.4

13. Lopez-Liuchi J.V., Meier C.A.: PPARγ: From adipose tissue to the atherosclerotic plaque. European Journal of Endocrinology 139: 363-364 (1998) IF 2.4

14. Lopez-Liuchi J.V., Meier C.A.: Therapy for type 2 diabetes: Where do we stand after the UK Prospective Diabetes Study? European Journal of Endocrinology 140: 4-6 (1999) IF 2.4

15. Meier C.A.: Ghrelin: Ein neues Hormon aus dem Magen Swiss Medical Forum 1 (8): 194 (2001)

16. Meier C.A.: Résistine - médiateur de la résistance à l'insuline? Swiss Medical Forum 1 (13): 346 (2001)

17. Meier C.A.: Editorial - Thyroid nodules & thyroid cancer Baillière's Best Practice & Research in Clinical Endocrinology & Metabolism 14 (4): vii - viii (2000) IF 4.9

18. Meier C.A.: Maladies endocrinologiques: du laboratoire à la prise en charge Caduceus p. 4-5 (June 2004)

19. Meier C.A., Gomez F.: Tout est endocrinologie Revue Médicale Suisse 1 (6): 403-404 (2005)

20. Meier C.A. Kiess W.: Editorial - Adipose tissue as an endocrine organ Best Practice & Research in Clinical Endocrinology & Metabolism 19 (4): vii (2005) IF 4.9

21. Meier C.A.: Baisser le cholestérol à tout prix, mis au point. Revue Médicale Suisse S45 (2007)

22. Meier C.A.: Schilddrüsenerkrankungen - Welcher Patient braucht weitere Abklärung, Behandlung und Nachkontrolle? Hausarzt Praxis No 5: 6 (2008)

23. Meier C.A.: Editorial comment Endokrinologie in der Praxis Therapeutische Umschau 68 (6): 7 (2011)

24. Meier C.A.: Editorial comment Andropause & Menopause Therapeutische Umschau 71 (4): 193 (2014)


25. Meier C.A.: Editorial comment Schilddüsenstörungen Der informierte Arzt, 4(6): 10 (2014)

26. Meier C.A., Metzger U.: Replik zum Artikel „SMB, AGLA und das Statin-Conundrum“ Schweizerische Aerztezeitung 95 (47): 1788 (2014)

27. Biller-Andorno N., Felder S., Meier C.A., Metzger U., Tag B.: Das Statin-Conundrum (zum Zweiten) Schweizerische Aerztezeitung 96 (22): 798-799 (2015)

4. Book Chapters 1. Meier C.A., Mäcke H., Ulmer N., Fridrich R.: Kurztests zur Vitalitätsprüfung von separierten Granulocyten.

Neue Aspekte radiologischer Diagnostik und Therapie (Editors: Bessler W. et al.), p.221-224, Hans Huber Verlag, Bern, Toronto (1986)

2. Meier C.A., Fabbro D., Jakob A., Hemmings B., Walter P.: Protein kinase C levels are increased in the liver of hypothyroid rats. Progress in Thyroid Research (Editors: Gordon A., Gross J., Hennemann G.), p.833-836, A.A. Balkema Publishers, Rotterdam (1991)

3. Meier C.A., Weintraub B.D.: Syndromes of resistance to thyroid hormone. Thyroid Diseases: Clinical Fundamentals and Therapy (Editors: Monaco F., Satta M.A., Shapiro B., Troncone L.), p.203-210, CRC Press Inc., Boca Raton, FL, USA. (1993)

4. Wondisford F., Meier C.A., Weintraub B.D.: Thyroid-stimulating hormone in health and disease. Endocrinology (Editor: DeGroot L.J.), 3rd edition, p.208-217, W.B. Saunders, Philadelphia, USA (1994)

5. Meier C.A.: Regulation of gene expression by nuclear hormone receptors. Frontiers in Endocrinology Vol 14 (Editors: De Bellis A., Schipani E.), p.107-128, Ares-Serono Symposia Publications (1995)

6. Meier C.A., Burger A.G.: Effects of pharmacological agents on thyroid hormone homeostasis. Werner and Ingbar's The Thyroid (Editors: Braverman L.E., Utiger R.D.), 7th edition, p.276-286, Lippincott-Raven, Philadelphia (1996)

7. Meier C.A., Burger A.G.: Effects of other pharmacological agents on thyroid function. Pharmacotherapeutics of the thyroid gland (Editors: Weetman A.P., Grossman A.), p.289-300, Springer Verlag, Heidelberg (1997)

8. Siegrist-Kaiser C.A., Juge-Aubry C.E., Shalev A., Pauli V., Rohner-Jeanrenaud F., Burger, A.G., Meier C.A.: Regulators of peroxisome proliferator-activated receptor phosphorylation. Leptin - The Voice of Adipose Tissue (Editors: Blum W.F., Kiess W., Rascher W.), p.50-57, J. A. Barth Verlag, Mannheim (1997)

9. Meier C.A.: Thyroid hormone and development: Brain and peripheral tissues. Thyroid diseases of infancy and childhood: Effects on behavior and intellectual development (Editors: Hauser P., Rovet J.), p.29-55. American Psychiatric Press, Washington DC (1999)

10. Meier C.A., Burger A.G.: Effects of drugs and other substances on thyroid hormone synthesis and metabolism. Werner and Ingbar's The Thyroid (Editors: Braverman L.E., Utiger R.D.), 8th edition, p.265-280, Lippincott-Raven, Philadelphia (2000)

11. Meier C.A.: Nontoxic goiter Surgery of the thyroid and parathyroid glands (Editor: Randolph G.W.), p. 61-69 W.B. Saunders, Philadelphia, USA (2003)

12. Meier C.A., Burger A.G.: Effects of drugs and other substances on thyroid hormone synthesis and metabolism. Werner and Ingbar's The Thyroid (Editors: Braverman L.E., Utiger R.D.), 9th edition, p. 229-247 Lippincott-Raven, Philadelphia (2005)

13. Procopiou M., Meier C.A.: Evaluation of thyroid nodules. Surgery of the thyroid and parathyroid glands (Editors: Oertli D., Udelsman R.), p. 45-60 Spinger, Heidelberg (2006)


14. Meier C.A.: Role of imaging in thyroid disease IDKD 2008 Syllabus, p. 243-250 Springer, Heidelberg (2008)

15. Thalmann S., Juge-Aubry C.E. and Meier C.A.: Explant cultures of white adipose tissue Adipose Tissue Protocols, Methods in Molecular Biology Vol. 456 (Editor: Yang K.), 2nd ed., p. 195-199 Humana Press, New Jersey, USA (2008)

16. Procopiou M., Meier C.A.: Evaluation of thyroid nodules. Surgery of the thyroid and parathyroid glands (Editors: Oertli D., Udelsman R.), 2nd edition, Spinger, Heidelberg (2012)

17. Meier C.A., Burger A.G.: Effects of drugs and other substances on thyroid hormone synthesis and metabolism. Werner and Ingbar's The Thyroid (Editors: Braverman L.E., Utiger R.D.), 10th edition Lippincott-Raven, Philadelphia (2013)

5. Monographs & Books 1. Meier C.A.: Thyroid nodules & thyroid cancer

Baillière's Best Practice and Research in Clinical Endocrinology and Metabolism 14 (4) (2000) IF 4.9

2. Meier C.A. and Kiess W.: Adipose tissue as an endocrine organ Best Practice & Research in Clinical Endocrinology & Metabolism 19 (4) (2005) IF 4.9

6. Diploma and Ph.D. theses 1997 Véronique Pauli, Diploma in Biochemistry: Direct effect of leptin on adipose tissue 1998 Eva Hammar, Diploma in Biochemistry: Regulation of the transcriptional activity of PPARs 2000 Nathalie Lameloise, Ph.D. Diploma in Biology: In vivo study of the effects of 3,5,3',5'-tetrac

on the heart and 5'-deiodinase II 2000 Anne Brawand Bron, M.D. thesis: Circulating activators of PPARs in human serum 2002 Alexandra Calmy, M.D. thesis: Recommendations for the treatment of hypercholesterolemia

in secondary prevention 2002 Lynne Salomon, Diploma in Biology: Metabolic regulators of cytokine production 2002 Magali G. Dreyer, Ph.D. thesis: Leptin has immunomodulatory effects on monocytes 2005 Emmanuel Somm, Ph.D. thesis: Production of IL-1Ra by adipose tissue: Regulation and

metabolic functions

7. Varia 1 Meier C.A.: Interview regarding the clinical use of recombinant human TSH.

Internal Medicine News 25 (23) (1992)

2. Meier C.A.: Interpretation of thyroid function tests. In: Recent advances in thyroid diagnostics, Heidelberg, 1993

3. Meier C.A.: Book review of L. Braverman: Diseases of the Thyroid. The Endocrinologist, 8 (4): 311 (1998)

4. Meier C.A.: Auto- / parakrine Effekte von Leptin auf das weisse und braune Fettgewebe. 25. Symposium of the Ludwig-Heilmeyer Society (1999).

5. Pralong F.P., Meier C.A.: Recommandations pour le diagnostic des tumeurs hypophysaires. www.ssedsged.ch. (2000)

6. Meier C.A.: Interview concernant la DHEA. Télévision de la Suisse Romande, 'A Bon Entendeur', 2002

7. Meier C.A.: TV Programm über die Hypothyreose. Sat1, '1x täglich', 2002


8. Meier C.A.: Clinical case series in thyroid diseases (no. 1 - 3) Lipha-Merck, 2002

9. Vischer U.M., Meier C.A.: Les promesses des instituts de bienêtre (le courrier des lecteurs). Le Temps, 24.6.03, p. 10

10. Meier C.A.: Interview über Anti-aging Medizin. Cash, 24.12.2003, No 52/1, p. 20-21

11. Meier C.A. (editor): Endocrine News 1-5 Lipha-Merck, 2004-2005

12. Meier C.A.: Pfizer Preis in klinischer Immunologie

13. Meier C.A.: Interview über Schilddrüsenkrankheiten La Tribune de Genève, 26.1.2004, p. 31

14. Meier C.A.: Interview über Schilddrüsenkrankheiten Femina, no 40 (3.10.2004), p. 50-51

15. Meier C.A.: Interview über Interessenkonflikte der Aerzte und die Pharmaindustrie Tribune de Genève 6-7.11.2004, p. 4

16. Meier C.A.: Interview über Jodprophylaxe um Kernkraftwerke Berner Zeitung 19.11.2004, p. 27

17. Meier C.A.: Interview über Jodprophylaxe um Kernkraftwerke Der Bund 23.11.2004, p.24

18. Meier C.A.: Interview über Jodprophylaxe um Kernkraftwerkes Neue Luzerner Zeitung 3.12.2004, p. 25

19. Meier C.A.: Interview über Anti-aging Medizin Femina, no. 51 (19.12.04), p. 44-45

20. Meier C.A.: Syndrome de Klinefelter (Interview) Revue Médicale Suisse 1 : 315-323 (2005)

21. Meier C.A.: Interview über Cholesterin und Herzinfarkt Tribune de Genève 22.11.2005, p. 44

22. Meier C.A.: Interview über 'Medical Humanities' während des Medizinstudiums Pulsations January 2006

23. Meier C.A.: Interview Reflexe 2/06

24. Meier C.A.: Interview über Kortisonpräparate Schweizer Familie, No 38, 21. Sept 2006; p 82-83

25. Meier C.A.: Interview Inkretine - ante portas Changing Diabetes Dialog, 17./18. Nov. 2006, p 9

26. Meier C.A.: Interview Neues Diabetes- und Endokrinologie-Ambulatorium Timeout, No 1, 2007, p. 9

27. Meier C.A.: Interview über modernes Diabetes-Management Medical Tribune 21 Sept. 2007 Jahrg 40, No 38, p. 6 Tribune médicale 21. sept. 2007 13è année, No 38, p.6

28. Meier C.A.: Interview über Schilddrüsenkrankheiten NNZ am Sonntag 18.11.2007, p. 82

29. Meier C.A.: Interview über Fortbildung für Hausärzte Leading Opinions - Kardiologie & Gefässmedizin 8: 4-5 (2008)

30. Meier C.A.: Interview über die Behandlung des Typ 2 Diabetes Sonntags Zeitung, 29.6.2008, p. 43

31. Meier C.A.: Interview über das Wachstum bei Kindern L'HEBDO, 3.7.2008, p. 33


32. Meier C.A.: Interview über ACCORD und ADVANCE Leading Opinions - Kardiologie & Gefässmedizin 8: Sonderpublikation 3 (2008)

33. Meier C.A.: Interview über die Andropause The Medical Journal No 5, p. 27-28 (2008)

34. Meier C.A.: Interview über die Andropause 76. Jahresversammlung der SGIM, 21.-23. Mai 2008, Lausanne

35. Meier C.A.: Interview "Anti-Aging: Lieber kein Testosteron" Neue Zuger Zeitung, Neue Nidwaldner Zeitung, Neue Luzerner Zeitung, Neue Obwaldner Zeitung, Neue Schwyzer Zeitung, Neue Urner Zeitung (2008)

36. Meier C.A.: Interview "Testosteron-Ersatztherapie: Risiken grösser als Nutzen" sprechzimmer.ch (2008)

37. Meier C.A.: Interview "Hormone für die «Wechseljahre des Mannes»?" 20 Minuten, Online-Ausgabe (2008)

38. Meier C.A.: Interview "L'andropause ne nécessite pas de mesure particulière" AP Associated Press, Nachrichtenredaktion Schweiz (2008)

39. Meier C.A.: Interview "Un traitement à la testostérone peut se révéler inutile et même dangereux" La Liberté (2008)

40. Meier C.A.: Interview "Hormone nehmen, wenn der Mann in die Wechseljahre kommt?" shortnews.de (2008)

41. Meier C.A.: Interview über die Andropause ("Der Begriff Andropause ist wenig hilfreich") Ars Medici No 9, p. 366-368 (2009)

42. Meier C.A.: BMI oder Bauchunmfang (Print Interview)? Neue Zürcher Zeitung, March 16th 2011, Nr. 63, p. 59

43. Meier C.A.: Round Table Diskussion über 'Kunst und Spital im Dialog'. value Dokumentation (2012)

44. Meier C.A: Den Schilddrüsenkrebs zuverlässig erkennen (Print Interview) NZZ am Sonntag, July 22nd 2012

45. Meier C.A.: Schilddrüsenkrebs (TV Interview) Schweizer Fernsehen, PULS, September 16th 2013

46. Stadtspital Triemli - Hauszeitung: Reportage 100 Jahre Dermatologisches Ambulatorium Timeout 2013, No. 5

47. Meier C.A.: Wieviel Medizin braucht der Mensch? Best of Basel, November 2013, p. 20-22

48. Meier C.A.: Troubles thyroïdiens (Print Interview) Le Temps, November 2nd 2013

49. Meier C.A.: La banalisation risquée des nouveaux anticoagulants (Print Interview) Le Temps, November 28th 2013

50. Meier C.A.: Empfehlungen des Medical Boards zum Einsatz von Statinen in der Primärprävention (Print Interview) Schweizerische Depeschenagentur, April 2nd 2014

51. Meier C.A.: Herzkrankheiten – Glaubenskrieg um Cholesterinsenker (TV Interview) TeleBärn, Tele M1, Tele 1 & TVO, gsundheit akut, May 12th-18th, 2014

52. Meier C.A.: SmarterMedicine -„Indikation Nichtstun – wenn weniger in der Medizin mehr ist” (Radio & Online Interview mit Pascal Biber) Radio SRF2 Kultur, Sendung Kontext, May 14th 2014

53. Meier C.A.: SmarterMedicine - Top 5 Liste (Radio Interview mit Gaudenz Wacker) Radio SRF1, Sendung Echo der Zeit, May 14th 2014

54. Meier C.A.: SmarterMedicine - Top 5 Liste (Print & Online Interview) TagesAnzeiger, May 17th 2014, p. 5


55. Meier C.A.: SmarterMedicine - Top 5 Liste (Print & Online Interview) Basler Zeitung, May 17th 2014

56. Meier C.A.: Les statines (Print Interview) La Tribune de Genève, June 27th 2014

57. Meier C.A.: Les statines (Print Interview) 24heures, June 27th 2014

58. Meier C.A: Jod ist das Salz in der Suppe (Print Interview) Migros-Zeitung, September 8th, 2014, Vol. 37

59. Meier C.A.: Unnötige Medizi - Ist weniger mehr? (TV Interview) TeleBärn, Tele M1, Tele 1 & TVO, gsundheit akut, December 14th-19th, 2014

60. Meier C.A.: Laudatio auf Dr. Urs Strebel, Präsident FAPK SGIM-Bulletin 2014, No 2, p. 13

61. Meier C.A.: Behandlung der Hypothyreose (Interview) Medical Tribune 2015.02.03

62. Meier C.A.: Gemeinsam zum Entscheid (Interview) Thema im Fokus, Dialog Ethik, April 2015, No. 120

63. Meier C.A.: Wie können Medizin und Oekonomie besser integriert werden? Intercura, Spring 2015, No. 5, p. 8-11

curriculum vitae 1. personal data - unispital basel...2002 - current commission for the board...

Documents